Development

Biogen will acquire an AMPA receptor potentiator for cognitive impairment associated with schizophrenia in a deal worth approximately $590 million.

Sartorius Stedim Biotech has launched a new automated parallel bioreactor system for perfusion culture.

Sensors and devices being developed by nGageIT Digital Health Solutions can track patient use of oral solid-dosage or injectable drugs.

Process validation is an extension of biologics development processes.

Successful outsourcing relationships for early phase analytics in drug development are driven by partnership.

Revisions to chapters on glass containers and elastomeric closures were canceled following review of comments.

GlobalData reports the need to shift away from egg-based manufacturing of vaccines in light of influenza-related deaths.

Modeling at various stages of the data analytics continuum aids scale comparison of a bioreactor.

PharmaMar has released the results of MI130004, a novel antibody drug conjucate created using a molecule of marine origin.

Avid Bioservices will provide commercial manufacture of an enzyme replacement therapy by Roivant Sciences' Enzyvant subsidiary.

The research partnership will focus on advancing regenerative medicine using porcine bioproducts.

The study suggests that circumventing evolution in cell factories can enable the commercialization of new biobased chemicals to large-scale.

Researchers at the University of Illinois developed a method to transplant pancreatic islet cells from pigs more easily to treat type I diabetes.

Ferring Pharmaceuticals will expand its biologics capabilities at its headquarters and manufacturing site in Saint-Prex, Switzerland.

A new report states that more research and clinical development must be done in the treatment of pain and addiction.

The acquisition strengthens an already existing collaboration between the companies to advance clinical development of therapies across multiple drug categories.

The companies will partner to further immuno-oncology research using humanized mice.

A collaboration between The Centre for Process Innovation and The Roslin Institute aims to develop commercially viable and scalable methods of producing biologics using transgenic animals.

The new Acquity Arc Bio System by Waters is specifically engineered to enable efficient transfer and improvement of bioseparation analytical methods.

The acquisition will strengthen Sanofi's R&D strategy and expands its franchise for rare blood disorders.

Corning will feature its 3D bioprinting technology and tools to support 3D cell culture at booth #1029 during the SLAS 2018 conference on Feb. 3-7, 2018 in San Diego, CA.

The funding from the Walloon Region will enable Univercells to start developing a manufacturing platform aimed at driving down costs of biosimilars manufacturing.

The acquisition strengthens Charles River Laboratories’ capabilities in the oncology and immunology therapeutic areas.

The acquisition, valued at EUR 520 million (US$631 million), would expand Takeda’s late-stage pipeline in gastroenterology and would extend an already existing collaboration between the two companies.

A Takeda and Denali collaboration includes three named programs for treating Alzheimer’s disease and other neurodegenerative diseases, using Denali’s antibody transport vehicle (ATV) technology to enhance blood-brain barrier penetration.